Search clinical trials for: Empagliflozin 10 MG Oral Tablet [Jardiance]

Total 954 results

Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
Ain Shams University
Drug Research Centre, Cairo, Egypt

Completed

The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin

Diabetes Mellitus | Pharmacokinetics | Pharmacodynamics

Egypt
Medical University of Vienna
Attoquant Diagnostics

Completed

EMPRA (EMPagliflozin and RAs in Kidney Disease) (EMPRA)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3

Austria
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
Medical University of Warsaw
Medical University of Graz; Medical University of Vienna; Poznan University of... and other collaborators

Recruiting

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY)

Acute Decompensated Heart Failure

Poland
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease (SHIELD)

Non-Alcoholic Fatty Liver Disease
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
Pharma Nueva

Not yet recruiting

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Healthy Vollunteer
University of Mississippi Medical Center
Eli Lilly and Company

Recruiting

Empagliflozin in ESKD - A Feasibility Study

Heart Failure | Kidney Failure, Chronic

United States
Royal Perth Hospital

Recruiting

Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans (EMPA-SNS)

Obesity | Type 2 Diabetes Mellitus | Metabolic Syndrome

Australia
Miulli General Hospital

Not yet recruiting

Empagliflozin and Atrial Fibrillation Treatment (EMPA-AF)

Heart Failure | Obesity | Diabetes Mellitus | Atrial Fibrillation

Italy
UCB Pharma SA

Completed

Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers

Healthy Volunteers

Netherlands
University Health Network, Toronto

Recruiting

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients (INFINITI2019)

Type 2 Diabetes | Kidney Transplant Recipients | Post-transplant Diabetes Mellitus

Canada
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Ketones, SGLT2, HFrEF

Heart Failure With Reduced Ejection Fraction | Type2diabetes

United States
LM Diagnósticos S.L.
AstraZeneca

Unknown

Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

Type2 Diabetes

Spain
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
Mario Negri Institute for Pharmacological Research
Boehringer Ingelheim

Withdrawn

SGLT2 Inhibitors in Glomerular Hyperfiltration (EMPATHY)

Obesity | Non-diabetic Chronic Kidney Disease
Medical University of Vienna

Completed

Empagliflozin in Post-Transplantation Diabetes Mellitus (EMPTRA-DM)

Posttransplant Diabetes Mellitus

Austria
Shanghai Zhongshan Hospital

Active, not recruiting

Remission of Type 2 Diabetes With Dapagliflozin (READ Trial) (READ)

Type 2 Diabetes

China
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
The Deutsche Diabetes Forschungsgesellschaft e.V.
Novo Nordisk A/S; Boehringer Ingelheim; Federal Ministry of Health, Germany; German... and other collaborators

Recruiting

Combined Active Treatment in Type 2 Diabetes With NASH (COMBAT_T2_NASH)

Type 2 Diabetes | Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

Germany, Austria
University Medical Center Groningen

Completed

Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE)

Heart Failure; With Decompensation | Heart Failure，Congestive | Heart Failure Acute

Netherlands
NHS Greater Glasgow and Clyde
University of Glasgow

Completed

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects (SUGAR-DM-HF)

Heart Failure | Diabetes Mellitus

United Kingdom
NYU Langone Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Boehringer...

Recruiting

Safety and Efficacy of Empagliflozin in Hemodialysis (SEED)

End Stage Renal Disease

United States
Anita Saraf
The Pittsburgh Foundation

Not yet recruiting

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease (EmpaCHD)

Heart Failure | Adult Congenital Heart Disease

United States
Maria Sklodowska-Curie National Research Institute...
Medical Research Agency, Poland

Recruiting

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT)

Cardiotoxicity

Poland
National Institute of Cardiology, Warsaw, Poland
Amsterdam UMC, location VUmc; University of Eastern Finland; Medical University...

Recruiting

Empagliflozin in Hypertrophic Cardiomyopathy (EMPA-REPAIR)

Heart Failure | Hypertrophic Cardiomyopathy

Poland
Centre Hospitalier Universitaire Vaudois

Completed

Empagliflozin and Renal Oxygenation in Healthy Volunteers (EMPA-REIN)

Nephropathy

Switzerland
University of Leicester
AstraZeneca; Royal Surrey County Hospital NHS Foundation Trust

Completed

The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes (SINGLED)

Type 2 Diabetes

United Kingdom
China National Center for Cardiovascular Diseases

Recruiting

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Hypertension | Pre-Heart Failure

China
Singapore General Hospital
Duke-NUS Graduate Medical School

Terminated

Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN) ((MEDiaN))

Diabetic Nephropathies

Singapore
The Lymphoma Academic Research Organisation
Institute of Cancer Research, United Kingdom

Recruiting

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

France, United Kingdom, Belgium
University of Oxford
Oxford Brookes University; The Leona M. and Harry B. Helmsley Charitable Trust

Terminated

Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia (DEPTH)

Diabetes Mellitus, Type 1

United Kingdom
SINA Health Education and Welfare Trust

Completed

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Polycystic Ovary Syndrome | Weight Gain | HbA1c

Pakistan
University Health Network, Toronto
Sunnybrook Health Sciences Centre; MOUNT SINAI HOSPITAL

Recruiting

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk (DAPA-SWEET)

Cardiovascular Risk Factor

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

Healthy Subjects

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

Healthy Subjects

Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
Damanhour University
Menoufia University

Unknown

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

Cardiomyopathies | Diabete Type 2 | Heart Failure With Reduced Ejection Fraction (HFrEF)
AstraZeneca

Not yet recruiting

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. (MIRO-CKD)

Chronic Kidney Disease

United States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
NHS Greater Glasgow and Clyde
University of Glasgow

Active, not recruiting

DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance (DAPARESIST)

Heart Failure

United Kingdom
Eisai Inc.

Completed

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Idiopathic Thrombocytopenic Purpura

United Kingdom
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
AstraZeneca

Not yet recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF)

Heart Failure and Impaired Kidney Function

United States, Canada, Finland, France, Germany, Italy, Spain, United Kingdom, Thailand, Vietnam, Korea, Republic of, Mexico, Peru, Philippines, Turkey, China, Taiwan, Austria, Slovakia, Chile, Argentina, Japan, Czechia, Greece, Hungary, ... and more
Cara Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States
Caroline M Kistorp
Rigshospitalet, Denmark; Herlev and Gentofte Hospital; Danish Heart Foundation

Completed

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk (SIMPLE)

Type2 Diabetes Mellitus

Denmark

Search clinical trials for: Empagliflozin 10 MG Oral Tablet [Jardiance]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations